Thallion financing a potential watershed
October 7, 2009 by stephenkilmer · Leave a Comment
Thallion Pharmaceuticals’ recent $8.85-million non-dilutive financing could turn out to be a pivotal event for cash-strapped Canadian healthcare companies facing the grim prospects of raising capital in today’s tough public equity markets. The deal, completed in July with Premium Brands Income Fund, essentially involved Thallion transferring all of its assets, with the exception of its [...]
Listen to BioTuesdays 
